? DESCRIPTION (provided by applicant): The PIs goals with this R15 proposal are studies on the thiamin diphosphate (ThDP)-dependent human 2-oxoglutarate dehydrogenase complex (OGDHc, also known as ?-ketoglutarate dehydrogenase; it comprises three component enzymes denoted with E1o-h, E2o-h and E3-h), the rate-limiting enzyme in the citric acid cycle (also known as the tricarboxylic or Krebs cycle), an enzyme critical for glucose metabolism in normal brain. OGDHc activity is diminished in the brain of Alzheimer's disease patients, which is characterized by reduced glucose metabolism and increased level of oxidative stress markers. A diminished OGDHc activity had also been correlated with other neurodegenerative diseases, including Parkinson's disease, Huntington disease, Wernike-Korsakoff disease and progressive subnuclear palsy. It is known that OGDHc is a sensitive target for a variety of oxidants generated during oxidative stress, including inhibition of OGDHc by peroxynitrite and nitric oxide, and by the reactive oxygen species (ROS), superoxide and H2O2, among other agents. OGDHc is not only a sensitive target of ROS, it can also produce superoxide and H2O2 in brain mitochondria. While earlier research attributed ROS generation by OGDHc to the E3-h component, the PI and collaborators have now shown definitively that (a) The ThDP-dependent E1o-h component in fact also produces superoxide anion and hydrogen peroxide, (b) Concomitantly, there is produced a ThDP-bound radical characterized by electron paramagnetic resonance spectroscopy (EPR). These products result from reaction of a ThDP-bound intermediate with dioxygen O2. Our contributions, and this proposal were made possible by the PI's group's recent success in producing full length, active recombinant versions of the human E1o-h and E2o-h components of this important complex in pure form and in significant amounts for the proposed research, while other groups address this issue mostly on intact brain mitochondrion, rather than with individual protein components of the human OGDHc. The OGDHc-h is located in the matrix of the mitochondrion where it is associated with the inner mitochondrial membrane, catalyzing the conversion of 2-oxoglutarate to succinyl-CoA according to: 2-oxoglutarate+NAD++CoA ? succinyl-CoA+NADH+H++CO2 (1) The overarching goal of our studies is an atomic-level explanation of: Which component (E1o-h and E3-h) is the major source of ROS production, consistent with the medical finding of reduced OGDHc activity in the brain with aging. Our long term goal is to provide an atomic explanation for the ROS findings in brain by identifying specific residues responsible for ROS formation, and those modified by ROS on all three components of the human OGDHc. Our immediate goals within the boundaries of the R15 program, are to initiate a logical sequence of projects, which will lead to achieving of our long-term goals, include: (a) Detection and kinetic characterization of thiamin-related intermediates on E1o-h and lipoamide-bound intermediates on E2o-h using a battery of kinetic and spectroscopic state-of-the-art methods developed in our group, as well as new methods EPR and ROS detection. We will determine the effect of OGDHc-h assembly, and of the contribution of the three individual components of OGDHc-h to ROS generation. No such studies are yet done on the human OGDHc. The mechanistic significance of these studies is to provide an understanding of how and where the ThDP-enamine radical formed by reaction of dioxygen with the enamine, receives special stabilization on the E1o-h; and which residues of E1o-h are the major contributors to ROS generation by OGDHc-h. (b) Development of an advanced laboratory course titled Introduction to Modern Biochemical Research to train both undergraduate and graduate students in state-of-the-art methodologies, with experiments strictly paralleling those proposed for the research program, and with the enzymes studied in our program; the tools to be taught will include, kinetics, spectroscopy (circular dichroism, MS, NMR, EPR), and basic tools of molecular biology and biochemistry. No such course exists at any Rutgers campus in Newark, hence it will serve the needs of both arts and sciences and the medical school in Newark. This course will also enable the Chemistry Department to at last offer a Biochemistry track; such a lab course is also highly recommended by the Am. Chem. Society. Significance and Innovation. An understanding of the mechanism by which OGDHc produces ROS, and how OGDHc activity could be altered by ROS is an important goal of the PI since it could provide insight to neurodegenerative diseases. This is the gap in our knowledge that our proposed research will help to fill. Methods for all experiments in the Specific Aim are in place i the PI's laboratories and are in published material, hence the proposed experiments carry little risk. Gary Gerfen at Albert Einstein College of Medicine has agreed to collaborate on the EPR studies. The close relationship between the course being proposed and the research being proposed is surely innovative and is in the spirit of the R-15 program.
|Effective start/end date||8/1/15 → 7/31/19|
- National Institute of General Medical Sciences: $369,360.00
- Clinical Neurology
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.